The findings may inform surveillance strategies and improve treatment outcomes.
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Distant metastasis emerged as the best candidate to be a surrogate endpoint for survival among patients receiving surgical treatment for upper tract urothelial carcinoma.
The proportion of patients with chronic kidney disease who die from cancer may be underappreciated.
The decision to discontinue the trials was based on data from preplanned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
A large study showed an increase in surveillance testing over time among patients with low-grade Ta non-muscle invasive bladder cancer.
Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.
There was no difference in the percentage of patients recovering at each time point for robot-assisted vs open radical cystectomy.
Increasing T stage has been associated with reduced long-term survival after trimodal therapy.
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Intravesical bacillus Calmette-Guérin remains effective in patients with prior radiation treatment for prostate cancer, according to a study.
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
The median progression-free survival was similar between the treatment arms.